TWiV reviews the vials labeled smallpox that were not, re-emergence of enterovirus D68 in Europe, efficacy of inactivated SARS-CoV-2 vaccine, and cellular correlates of protection for an oral influenza virus vaccine. Click arrow to playDownload TWiV 832 (77 MB .mp3, 128 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv
On February 27, 2021, the FDA issued an emergency use authorization for a one-dose SARS-CoV-2 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson.
The TWiV team reveals that recent mumps virus outbreaks in the US are due to waning vaccine efficacy, and an intranasally delivered small interfering RNA that controls West Nile infection in the brain. ï»¿<span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”>ï»¿</span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”>ï»¿</span>&lt;span data-mce-type=”bookmark” …
The TWiV team takes on an experimental plant-based poliovirus vaccine, contradictory findings on the efficacy of Flumist, waning protection conferred by Zostavax, and a new adjuvanted subunit zoster vaccine. You can find TWiV #403 at microbe.tv/twiv, or listen below. [powerpress url=”http://traffic.libsyn.com/twiv/TWiV403.mp3″] Click arrow to play Download TWiV 403 (70 MB .mp3, 96 min) Subscribe (free): iTunes, RSS, email Become a patron of TWiV!